Celldex Therapeutics, Inc. — Director's Dealing 2025

Jun 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2025-06-05

Reporting Person: Torres Denice (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-05	Non-Qualified Stock Option (right to buy)	$19.53	A	33000	Acquired	2035-06-05	Common Stock (33000)	Direct

Footnotes

F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

F2: Such option vests in three equal annual installments beginning June 5, 2026.